PMC:7276974
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 38-43 | SP_6;NCBITaxon:9606 | denotes | human |
T2 | 49-59 | SP_7 | denotes | SARS-CoV-2 |
T3 | 73-79 | UBERON:0001969 | denotes | plasma |
T4 | 96-102 | UBERON:0007023 | denotes | adults |
T5 | 108-116 | SP_7 | denotes | COVID-19 |
T6 | 268-273 | SP_6;NCBITaxon:9606 | denotes | human |
T7 | 279-289 | SP_7 | denotes | SARS-CoV-2 |
T8 | 303-309 | UBERON:0001969 | denotes | plasma |
T9 | 326-332 | UBERON:0007023 | denotes | adults |
T10 | 345-355 | SP_7 | denotes | SARS-CoV-2 |
T11 | 562-568 | UBERON:0007023 | denotes | adults |
T12 | 599-609 | SP_7 | denotes | SARS-CoV-2 |
T13 | 635-649 | UBERON:0001728 | denotes | nasopharyngeal |
T14 | 653-666 | UBERON:0001179 | denotes | oropharyngeal |
T15 | 732-737 | UBERON:0001443 | denotes | chest |
T16 | 762-771 | UBERON:0001982 | denotes | capillary |
T17 | 1167-1172 | NCBITaxon:10239 | denotes | viral |
T18 | 1187-1198 | NCBITaxon:11118 | denotes | coronavirus |
T19 | 1213-1221 | SP_7 | denotes | COVID-19 |
T20 | 1244-1249 | NCBITaxon:10239 | denotes | viral |
T21 | 1291-1301 | SP_7 | denotes | SARS-CoV-2 |
T22 | 1321-1327 | UBERON:0001969 | denotes | plasma |
T23 | 1396-1407 | GO:0015671 | denotes | oxygenation |
T24 | 1443-1448 | UBERON:0000062 | denotes | organ |
T25 | 1502-1507 | UBERON:0000178 | denotes | blood |
T26 | 1546-1549 | GO:0071735 | denotes | IgA |
T27 | 1566-1575 | GO:0007565 | denotes | pregnancy |
T28 | 1653-1659 | UBERON:0001969 | denotes | plasma |
T29 | 1678-1688 | DG_28 | denotes | remdesivir |
T30 | 1706-1714 | SP_7 | denotes | COVID-19 |
T31 | 1887-1897 | SP_7 | denotes | SARS-CoV-2 |
T32 | 1898-1903 | SP_6;NCBITaxon:9606 | denotes | human |
T33 | 1917-1923 | UBERON:0001969 | denotes | plasma |
T34 | 1997-2005 | SP_7 | denotes | COVID-19 |
T35 | 2059-2069 | SP_7 | denotes | SARS-CoV-2 |
T36 | 2070-2078 | GO:0042571 | denotes | antibody |
T37 | 2199-2202 | NCBITaxon:10376 | denotes | HBV |
T38 | 2214-2218 | NCBITaxon:10298 | denotes | HTLV |
T39 | 2269-2277 | SP_7 | denotes | COVID-19 |
T40 | 2332-2346 | UBERON:0001728 | denotes | nasopharyngeal |
T41 | 2372-2382 | SP_7 | denotes | SARS-CoV-2 |
T42 | 2397-2403 | UBERON:0001969 | denotes | Plasma |
T43 | 2474-2479 | UBERON:0000178 | denotes | Blood |
T44 | 2584-2594 | SP_7 | denotes | SARS-CoV-2 |
T45 | 2595-2601 | UBERON:0001969 | denotes | plasma |
T46 | 2667-2673 | UBERON:0001969 | denotes | plasma |
T47 | 2687-2693 | UBERON:0001969 | denotes | plasma |
T48 | 2732-2742 | SP_7 | denotes | SARS-CoV-2 |
T49 | 2743-2751 | GO:0042571 | denotes | antibody |
T50 | 2807-2817 | SP_7 | denotes | SARS-CoV-2 |
T51 | 2818-2826 | GO:0042571 | denotes | antibody |
T52 | 3529-3534 | GO:0016265 | denotes | Death |
T53 | 3748-3756 | SP_7 | denotes | COVID-19 |
T54 | 3820-3829 | CHEBI:31781;DG_23;CHEBI:31781 | denotes | lopinavir |
T55 | 3831-3840 | DG_30 | denotes | ritonavir |
T56 | 3879-3887 | SP_7 | denotes | COVID-19 |
T57 | 4045-4051 | UBERON:0002405 | denotes | immune |
T58 | 4052-4058 | UBERON:0001969 | denotes | plasma |
T59 | 4305-4315 | SP_7 | denotes | SARS-CoV-2 |
T60 | 4316-4322 | UBERON:0001969 | denotes | plasma |
T61 | 4338-4344 | UBERON:0001969 | denotes | plasma |
T62 | 4681-4686 | UBERON:0000178 | denotes | blood |
T63 | 4859-4869 | SP_7 | denotes | SARS-CoV-2 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 73-79 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T2 | 303-309 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T3 | 732-737 | Body_part | denotes | chest | http://purl.org/sig/ont/fma/fma9576 |
T4 | 762-771 | Body_part | denotes | capillary | http://purl.org/sig/ont/fma/fma63194 |
T5 | 1321-1327 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T6 | 1443-1448 | Body_part | denotes | organ | http://purl.org/sig/ont/fma/fma67498 |
T7 | 1502-1507 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
T8 | 1546-1549 | Body_part | denotes | IgA | http://purl.org/sig/ont/fma/fma62874 |
T9 | 1653-1659 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T10 | 1917-1923 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T11 | 2070-2078 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T12 | 2194-2197 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
T13 | 2397-2403 | Body_part | denotes | Plasma | http://purl.org/sig/ont/fma/fma62970 |
T14 | 2474-2479 | Body_part | denotes | Blood | http://purl.org/sig/ont/fma/fma9670 |
T15 | 2595-2601 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T16 | 2667-2673 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T17 | 2687-2693 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T18 | 2743-2751 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T19 | 2818-2826 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T20 | 4052-4058 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T21 | 4316-4322 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T22 | 4338-4344 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T23 | 4681-4686 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
T24 | 4870-4873 | Body_part | denotes | arm | http://purl.org/sig/ont/fma/fma24890 |
T25 | 4897-4900 | Body_part | denotes | arm | http://purl.org/sig/ont/fma/fma24890 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 732-737 | Body_part | denotes | chest | http://purl.obolibrary.org/obo/UBERON_0001443 |
T2 | 762-771 | Body_part | denotes | capillary | http://purl.obolibrary.org/obo/UBERON_0001982 |
T3 | 1443-1448 | Body_part | denotes | organ | http://purl.obolibrary.org/obo/UBERON_0000062 |
T4 | 1502-1507 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
T5 | 2474-2479 | Body_part | denotes | Blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
T6 | 3115-3120 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T7 | 3540-3545 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T8 | 3911-3916 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T9 | 4681-4686 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
T10 | 4870-4873 | Body_part | denotes | arm | http://purl.obolibrary.org/obo/UBERON_0001460 |
T11 | 4897-4900 | Body_part | denotes | arm | http://purl.obolibrary.org/obo/UBERON_0001460 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 49-57 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T2 | 108-116 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 279-287 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T4 | 345-353 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T5 | 356-365 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T6 | 599-607 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T7 | 610-619 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T8 | 1187-1211 | Disease | denotes | coronavirus disease-2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T9 | 1213-1221 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T10 | 1291-1299 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T11 | 1437-1456 | Disease | denotes | multi-organ failure | http://purl.obolibrary.org/obo/MONDO_0043726 |
T12 | 1469-1487 | Disease | denotes | allergic reactions | http://purl.obolibrary.org/obo/MONDO_0000605|http://purl.obolibrary.org/obo/MONDO_0005271 |
T14 | 1469-1477 | Disease | denotes | allergic | http://purl.obolibrary.org/obo/MONDO_0004980 |
T15 | 1546-1560 | Disease | denotes | IgA deficiency | http://purl.obolibrary.org/obo/MONDO_0001341 |
T16 | 1706-1714 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T17 | 1887-1895 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T18 | 1997-2005 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T19 | 2059-2067 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T20 | 2177-2187 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
T21 | 2269-2277 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T22 | 2372-2380 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T23 | 2584-2592 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T24 | 2732-2740 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T25 | 2807-2815 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T26 | 3748-3756 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T27 | 3879-3887 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T28 | 3982-3991 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T29 | 4305-4313 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T30 | 4859-4867 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 38-43 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T2 | 73-79 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T3 | 118-119 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T4 | 142-143 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T5 | 163-164 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T6 | 193-203 | http://purl.obolibrary.org/obo/BFO_0000030 | denotes | Objectives |
T7 | 208-211 | http://purl.obolibrary.org/obo/PR_000001343 | denotes | aim |
T8 | 268-273 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T9 | 303-309 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T10 | 388-389 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T11 | 572-574 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
T12 | 627-631 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
T13 | 732-737 | http://www.ebi.ac.uk/efo/EFO_0000965 | denotes | chest |
T14 | 799-801 | http://purl.obolibrary.org/obo/CLO_0001527 | denotes | 94 |
T15 | 1036-1037 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T16 | 1274-1282 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T17 | 1321-1327 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T18 | 1387-1395 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T19 | 1443-1448 | http://purl.obolibrary.org/obo/UBERON_0003103 | denotes | organ |
T20 | 1502-1507 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
T21 | 1502-1507 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
T22 | 1526-1529 | http://purl.obolibrary.org/obo/CL_0000990 | denotes | CDC |
T23 | 1653-1659 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T24 | 1898-1903 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T25 | 1917-1923 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T26 | 2019-2026 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T27 | 2102-2103 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T28 | 2330-2331 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T29 | 2397-2403 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | Plasma |
T30 | 2474-2479 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | Blood |
T31 | 2474-2479 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | Blood |
T32 | 2529-2534 | http://purl.obolibrary.org/obo/CLO_0053711 | denotes | a 2:1 |
T33 | 2595-2601 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T34 | 2667-2673 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T35 | 2687-2693 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T36 | 2704-2710 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
T37 | 2790-2796 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
T38 | 2862-2863 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T39 | 3192-3202 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activities |
T40 | 3252-3262 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activities |
T41 | 3643-3655 | http://purl.obolibrary.org/obo/OBI_0000245 | denotes | Organization |
T42 | 3758-3759 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T43 | 3893-3894 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T44 | 4003-4004 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T45 | 4026-4027 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T46 | 4052-4058 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T47 | 4277-4282 | http://purl.obolibrary.org/obo/CLO_0053711 | denotes | a 2:1 |
T48 | 4316-4322 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T49 | 4338-4344 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T50 | 4351-4352 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T51 | 4681-4686 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
T52 | 4681-4686 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
T53 | 4870-4873 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arm |
T54 | 4897-4900 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arm |
T55 | 5019-5020 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T56 | 5036-5040 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
T57 | 5113-5114 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T58 | 5588-5591 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T59 | 5631-5632 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 772-778 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T2 | 845-851 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T3 | 1162-1178 | Chemical | denotes | anti-viral agent | http://purl.obolibrary.org/obo/CHEBI_22587 |
T4 | 1239-1255 | Chemical | denotes | anti-viral agent | http://purl.obolibrary.org/obo/CHEBI_22587 |
T5 | 1678-1688 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T6 | 2221-2223 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
T7 | 3307-3313 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T8 | 3354-3360 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T9 | 3398-3404 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T10 | 3820-3829 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T11 | 3831-3840 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T12 | 4659-4664 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T13 | 4746-4751 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T14 | 5614-5620 | Chemical | denotes | Letter | http://purl.obolibrary.org/obo/CHEBI_6446 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-117 | Sentence | denotes | Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: |
T2 | 118-192 | Sentence | denotes | A structured summary of a study protocol for a randomized controlled trial |
T3 | 193-203 | Sentence | denotes | Objectives |
T4 | 204-366 | Sentence | denotes | The aim of this study is to evaluate the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection. |
T5 | 367-379 | Sentence | denotes | Trial Design |
T6 | 380-518 | Sentence | denotes | This is a prospective, single-center, phase 2, randomized, controlled trial that is blinded to participants and clinical outcome assessor. |
T7 | 519-531 | Sentence | denotes | Participants |
T8 | 532-1091 | Sentence | denotes | Eligible participants include adults (≥ 18 years) with evidence of SARS-CoV-2 infection by PCR test of nasopharyngeal or oropharyngeal swab within 14 days of randomization, evidence of infiltrates on chest radiography, peripheral capillary oxygen saturation (SpO2) ≤ 94% on room air, and/or need for supplemental oxygen, non-invasive mechanical ventilation, or invasive mechanical ventilation, who are willing and able to provide written informed consent prior to performing study procedures or who have a legally authorized representative available to do so. |
T9 | 1092-1576 | Sentence | denotes | Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 <24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy. |
T10 | 1577-1669 | Sentence | denotes | Included participants will be hospitalized at the time of randomization and plasma infusion. |
T11 | 1670-1728 | Sentence | denotes | *Use of remdesivir as treatment for COVID-19 is permitted. |
T12 | 1729-1820 | Sentence | denotes | The study will be undertaken at Columbia University Irving Medical Center in New York, USA. |
T13 | 1821-1848 | Sentence | denotes | Intervention and comparator |
T14 | 1849-1924 | Sentence | denotes | The investigational treatment is anti-SARS-CoV-2 human convalescent plasma. |
T15 | 1925-2119 | Sentence | denotes | To procure the investigational treatment, volunteers who recovered from COVID-19 will undergo testing to confirm the presence of anti-SARS-CoV-2 antibody to the spike trimer at a 1:400 dilution. |
T16 | 2120-2241 | Sentence | denotes | Donors will also be screened for transfusion-transmitted infections (e.g. HIV, HBV, HCV, WNV, HTLV-I/II, T. cruzi, ZIKV). |
T17 | 2242-2396 | Sentence | denotes | If donors have experienced COVID-19 symptoms within 28 days, they will be screened with a nasopharyngeal swab to confirm they are SARS-CoV-2 PCR-negative. |
T18 | 2397-2487 | Sentence | denotes | Plasma will be collected using standard apheresis technology by the New York Blood Center. |
T19 | 2488-2674 | Sentence | denotes | Study participants will be randomized in a 2:1 ratio to receive one unit (200 – 250 mL) of anti-SARS-CoV-2 plasma versus one unit (200 – 250 mL) of the earliest available control plasma. |
T20 | 2675-2900 | Sentence | denotes | The control plasma cannot be tested for presence of anti-SARS-CoV-2 antibody prior to the transfusion, but will be tested for anti- SARS-CoV-2 antibody after the transfusion to allow for a retrospective per-protocol analysis. |
T21 | 2901-2914 | Sentence | denotes | Main outcomes |
T22 | 2915-2968 | Sentence | denotes | The primary endpoint is time to clinical improvement. |
T23 | 2969-3145 | Sentence | denotes | This is defined as time from randomization to either discharge from the hospital or improvement by one point on the following seven-point ordinal scale, whichever occurs first. |
T24 | 3146-3148 | Sentence | denotes | 1. |
T25 | 3149-3202 | Sentence | denotes | Not hospitalized with resumption of normal activities |
T26 | 3203-3205 | Sentence | denotes | 2. |
T27 | 3206-3262 | Sentence | denotes | Not hospitalized, but unable to resume normal activities |
T28 | 3263-3265 | Sentence | denotes | 3. |
T29 | 3266-3313 | Sentence | denotes | Hospitalized, not requiring supplemental oxygen |
T30 | 3314-3316 | Sentence | denotes | 4. |
T31 | 3317-3360 | Sentence | denotes | Hospitalized, requiring supplemental oxygen |
T32 | 3361-3363 | Sentence | denotes | 5. |
T33 | 3364-3451 | Sentence | denotes | Hospitalized, requiring high-flow oxygen therapy or non-invasive mechanical ventilation |
T34 | 3452-3454 | Sentence | denotes | 6. |
T35 | 3455-3525 | Sentence | denotes | Hospitalized, requiring ECMO, invasive mechanical ventilation, or both |
T36 | 3526-3528 | Sentence | denotes | 7. |
T37 | 3529-3534 | Sentence | denotes | Death |
T38 | 3535-3757 | Sentence | denotes | This scale, designed to assess clinical status over time, was based on that recommended by the World Health Organization for use in determining efficacy end-points in clinical trials in hospitalized patients with COVID-19. |
T39 | 3758-4059 | Sentence | denotes | A recent clinical trial evaluating the efficacy and safety of lopinavir- ritonavir for patients hospitalized with severe COVID-19 used a similar ordinal scale, as have recent clinical trials of novel therapeutics for severe influenza, including a post-hoc analysis of a trial evaluating immune plasma. |
T40 | 4060-4221 | Sentence | denotes | The primary safety endpoints are cumulative incidence of grade 3 and 4 adverse events and cumulative incidence of serious adverse events during the study period. |
T41 | 4222-4235 | Sentence | denotes | Randomization |
T42 | 4236-4386 | Sentence | denotes | Study participants will be randomized in a 2:1 ratio to receive anti-SARS-CoV-2 plasma versus control plasma using a web-based randomization platform. |
T43 | 4387-4536 | Sentence | denotes | Treatment assignments will be generated using randomly permuted blocks of different sizes to minimize imbalance while also minimizing predictability. |
T44 | 4537-4555 | Sentence | denotes | Blinding (masking) |
T45 | 4556-4676 | Sentence | denotes | The study participants and the clinicians who will evaluate post-treatment outcomes will be blinded to group assignment. |
T46 | 4677-4763 | Sentence | denotes | The blood bank and the clinical research team will not be blinded to group assignment. |
T47 | 4764-4802 | Sentence | denotes | Numbers to be randomized (sample size) |
T48 | 4803-4901 | Sentence | denotes | We plan to enroll 129 participants, with 86 in the anti-SARS-CoV-2 arm, and 43 in the control arm. |
T49 | 4902-4985 | Sentence | denotes | Among the participants, we expect ~70% or n = 72 will achieve clinical improvement. |
T50 | 4986-5135 | Sentence | denotes | This will yield an 80% power for a one-sided Wald test at 0.15 level of significance under the proportional hazards model with a hazard ratio of 1.5. |
T51 | 5136-5148 | Sentence | denotes | Trial Status |
T52 | 5149-5196 | Sentence | denotes | Protocol AAAS9924, Version 17APR2020, 4/17/2020 |
T53 | 5197-5218 | Sentence | denotes | Start of recruitment: |
T54 | 5219-5233 | Sentence | denotes | April 20, 2020 |
T55 | 5234-5257 | Sentence | denotes | Recruitment is ongoing. |
T56 | 5258-5276 | Sentence | denotes | Trial registration |
T57 | 5277-5308 | Sentence | denotes | ClinicalTrials.gov: NCT04359810 |
T58 | 5309-5336 | Sentence | denotes | Date of trial registration: |
T59 | 5337-5351 | Sentence | denotes | April 24, 2020 |
T60 | 5352-5378 | Sentence | denotes | Retrospectively registered |
T61 | 5379-5392 | Sentence | denotes | Full protocol |
T62 | 5393-5501 | Sentence | denotes | The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). |
T63 | 5502-5682 | Sentence | denotes | In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 338-365 | Phenotype | denotes | severe SARS-CoV-2 infection | http://purl.obolibrary.org/obo/HP_0033141 |
T2 | 1546-1560 | Phenotype | denotes | IgA deficiency | http://purl.obolibrary.org/obo/HP_0002720 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
3 | 38-43 | Species | denotes | human | Tax:9606 |
4 | 49-59 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
5 | 108-116 | Disease | denotes | COVID-19 | MESH:C000657245 |
9 | 268-273 | Species | denotes | human | Tax:9606 |
10 | 279-289 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
11 | 345-365 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
13 | 475-487 | Species | denotes | participants | Tax:9606 |
25 | 541-553 | Species | denotes | participants | Tax:9606 |
26 | 1291-1301 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
27 | 1586-1598 | Species | denotes | participants | Tax:9606 |
28 | 772-778 | Chemical | denotes | oxygen | MESH:D010100 |
29 | 845-851 | Chemical | denotes | oxygen | MESH:D010100 |
30 | 599-619 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
31 | 1187-1211 | Disease | denotes | coronavirus disease-2019 | MESH:C000657245 |
32 | 1213-1221 | Disease | denotes | COVID-19 | MESH:C000657245 |
33 | 1437-1456 | Disease | denotes | multi-organ failure | MESH:D009102 |
34 | 1469-1487 | Disease | denotes | allergic reactions | MESH:D004342 |
35 | 1546-1560 | Disease | denotes | IgA deficiency | MESH:D017098 |
38 | 1678-1688 | Chemical | denotes | remdesivir | MESH:C000606551 |
39 | 1706-1714 | Disease | denotes | COVID-19 | MESH:C000657245 |
56 | 2214-2223 | Gene | denotes | HTLV-I/II | |
57 | 2086-2091 | Gene | denotes | spike | Gene:43740568 |
58 | 1898-1903 | Species | denotes | human | Tax:9606 |
59 | 2225-2233 | Species | denotes | T. cruzi | Tax:5693 |
60 | 2235-2239 | Species | denotes | ZIKV | Tax:64320 |
61 | 2372-2382 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
62 | 2494-2506 | Species | denotes | participants | Tax:9606 |
63 | 1887-1897 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
64 | 2059-2069 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
65 | 2584-2594 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
66 | 2732-2742 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
67 | 2807-2817 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
68 | 1997-2005 | Disease | denotes | COVID-19 | MESH:C000657245 |
69 | 2177-2187 | Disease | denotes | infections | MESH:D007239 |
70 | 2194-2197 | Disease | denotes | HIV | MESH:D015658 |
71 | 2269-2277 | Disease | denotes | COVID-19 | MESH:C000657245 |
73 | 3307-3313 | Chemical | denotes | oxygen | MESH:D010100 |
75 | 3354-3360 | Chemical | denotes | oxygen | MESH:D010100 |
77 | 3398-3404 | Chemical | denotes | oxygen | MESH:D010100 |
79 | 3529-3534 | Disease | denotes | Death | MESH:D003643 |
85 | 3734-3742 | Species | denotes | patients | Tax:9606 |
86 | 3845-3853 | Species | denotes | patients | Tax:9606 |
87 | 3820-3840 | Chemical | denotes | lopinavir- ritonavir | MESH:C558899 |
88 | 3748-3756 | Disease | denotes | COVID-19 | MESH:C000657245 |
89 | 3879-3887 | Disease | denotes | COVID-19 | MESH:C000657245 |
92 | 4242-4254 | Species | denotes | participants | Tax:9606 |
93 | 4305-4315 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
95 | 4566-4578 | Species | denotes | participants | Tax:9606 |
99 | 4825-4837 | Species | denotes | participants | Tax:9606 |
100 | 4912-4924 | Species | denotes | participants | Tax:9606 |
101 | 4859-4869 | Species | denotes | SARS-CoV-2 | Tax:2697049 |